Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Measurement of Free Polysaccharide in Tetanus Toxoid-Conjugate Vaccine Using Antibody/Ammonium Sulfate Precipitation

  • Yoo, Tae-Hyeon (Green Cross Vaccine Corporation) ;
  • Kim, Hyun-Sung (Green Cross Vaccine Corporation, Department of Boitechnology and Bioengineering, Inha University) ;
  • Park, Sung-Sik (Green Cross Vaccine Corporation) ;
  • Bang, Eun-Young (Green Cross Vaccine Corporation) ;
  • Oh, Yong-K. (Green Cross Vaccine Corporation) ;
  • Kim, Li-Seop (Green Cross Vaccine Corporation) ;
  • Kim, Hun (Green Cross Vaccine Corporation, Department of Molecular Science and Technology) ;
  • Hur, Byung-Ki (Department of Boitechnology and Bioengineering, Inha University) ;
  • Ryu, Yeon-Woo (Department of Molecular Science and Technology, Ajou University) ;
  • Kim, Jong-Su (Green Cross Vaccine Corporation)
  • Published : 2003.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

A method that effectively precipitates capsular polysaccharide of Haemophilus influenzae type b (polyribosylribitol phosphate, PRP) conjugated to tetanus toxoid (TT), PRP TT in a liquid vaccine has been developed to measure free PRP present in TT-conjugate vaccine. The method involves adding anti-TT antibody and ammonium sulfate to precipitate PRP-TT conjugate and measuring free PRP in tile supernatant. This new method provides a complete precipitation of the total PRP-TT, and provides an accurate and reproducible measurements of free PRP. The accuracy of the assay was confirmed by spiking known amounts of unconjugated PRP to PRP-TT conjugate, and the new method was found to have no effect on free PRP while precipitating PRP-TT. The published acid precipitation method did not produce reproducible results due to incomplete precipitation of PRP-TT, especially when the vaccine is formulated in a salt-buffered solution.

Keywords

References

  1. Bae, C. S., K. N. Park, S. J. Ahn, S. J. Kim, and B. K. Hur. 2002. Development of a quardrivalent combined DTaP-HepB vaccine with a low toxicity and a stable HBsAg immunogenicity. J. Microbiol. Biotechnol. 12: 787-792
  2. J. Microbiol. Biotechnol. v.12 Development of a quardrivalent combined DTaP-HepB vaccine with a low toxicity and a stable HBsAg immunogenicity Bae,C.S.;K.N.Park;S.J.Ahn;S.J.Kim;B.K.Hur
  3. Pediatr. Infect. Dis. J. v.10 Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b(HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group Black,S.B.;H.R.Shinefield;B.Fireman;R.Hiatt;M.Polen;E.Vittinghoff https://doi.org/10.1097/00006454-199102000-00004
  4. Pediatr. Infect. Dis. J. v.11 Immunization with oligosaccharide conjugate Haemophilus influenzae type b(HbOC) vaccine on a large health maintenance organization poplation: Extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group Black,S.B.;H.R.Shinefield
  5. Infect. Immun. v.40 Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates Chu,C.;R.Scheerson;J.B.Robbins;S.C.Rastogi
  6. Guide to Protein Purification England,S.;S.Seifter;M.P.Deutscher(ed.)
  7. N. Engl. J. Med. v.317 Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy Eskola,J.;H.Peltola;A.K.Takala;H.Kayhty;M.Hakulinen;V.Karanko;E.Kela;P.Rekola;P.R.Ronnberg;J.S.Samuelson;L.K.Gordon;P.H.Makela https://doi.org/10.1056/NEJM198709173171201
  8. European Pharmacopoeia(4th Ed.) The Directorate for the Quality of Medicines of Council of Europe
  9. J. Infect. Dis. v.103 A quantitative immunochemical measure of the primary interaction between I*BSA and antibody Farr,R.S. https://doi.org/10.1093/infdis/103.3.239
  10. Biologicals v.26 A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus influenzae type b in PRP-tetanus toxoid conjugate vaccine Guo,Y.Y.;R.Anderson;J.Mclver;R.K.Gupta;G.R.Siber https://doi.org/10.1006/biol.1997.0121
  11. Experimental Immunochemistry Carbohydrates estimates Kabat,E.A.;M.Mayer;G.Thomas(ed.)
  12. Am. J. Dis. Child. v.145 Antibody responses to four Haemophilus influenzae type b conjugate vaccines Kaythy,H.;J.Eskola;H.Peltola;P.R.Ronnberg;E.Kela;V.karanko;L.Saarinen
  13. Dev. Biol. Stand. v.87 Stability testing in Haemophilus influenzae type b conjugate vaccines Klug,B.
  14. J. Pharmaceut. Biomed. v.21 Quantitation of low level unconjugated polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC/PAD following rapid separation by deoxycholate/HCI Lei,Q.P.;D.H.Lamb;R.Heller;P.Pietobon https://doi.org/10.1016/S0731-7085(99)00183-1
  15. Dev. Biol. v.103 Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines Lei,Q.P.;A.G.Shannon;R.Heller;D.H.Lamb
  16. Pediatrics v.60 Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland Peltola,H.;H.Kayhty;A.Sivenon;H.Makela
  17. J. Exp. Med. v.152 Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates Scheerson,R.;O.Barrera;A.Sutton https://doi.org/10.1084/jem.152.2.361
  18. Pediatrics v.52 Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b Smith,D.H.;G.Peter;D.L.Ingram;A.L.Harding;P.Anderson
  19. J. Pediatr. v.113 Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease Weinberg,G.A.;D.M.Granoff https://doi.org/10.1016/S0022-3476(88)80369-X